Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome by Shaffer, Brian C. et al.
JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T
Author affiliations appear at the end of this
article.
Published online ahead of print at
www.jco.org on April 4, 2016.
Authors’ disclosures of potential conflicts
of interest are found in the article online at
www.jco.org. Author contributions are
found at the end of this article.
Corresponding author: Brian C. Shaffer,
MD, Memorial Sloan Kettering Cancer
Center, 1275 York Ave, New York, NY
10065; e-mail: shaffeb1@mskcc.org.
© 2016 by American Society of Clinical
Oncology
0732-183X/16/3416w-1864w/$20.00
DOI: 10.1200/JCO.2015.65.0515
Scoring System Prognostic of Outcome in Patients
Undergoing Allogeneic Hematopoietic Cell Transplantation
for Myelodysplastic Syndrome
Brian C. Shaffer, Kwang Woo Ahn, Zhen-Huan Hu, Taiga Nishihori, Adriana K. Malone, David Valca´rcel,
Michael R. Grunwald, Ulrike Bacher, Betty Hamilton, Mohamed A. Kharfan-Dabaja, Ayman Saad, Corey Cutler,
Erica Warlick, Ran Reshef, Baldeep Mona Wirk, Mitchell Sabloff, Omotayo Fasan, Aaron Gerds, David Marks,
Richard Olsson, William Allen Wood, Luciano J. Costa, Alan M. Miller, Jorge Cortes, Andrew Daly,
Tamila L. Kindwall-Keller, Rammurti Kamble, David A. Rizzieri, Jean-Yves Cahn, Robert Peter Gale,
Basem William, Mark Litzow, Peter H. Wiernik, Jane Liesveld, Bipin N. Savani, Ravi Vij, Celalettin Ustun,
Edward Copelan, Uday Popat, Matt Kalaycio, Richard Maziarz, Edwin Alyea, Ron Sobecks, Steven Pavletic,
Martin Tallman, and Wael Saber
A B S T R A C T
Purpose
To develop a system prognostic of outcome in those undergoing allogeneic hematopoietic cell
transplantation (allo HCT) for myelodysplastic syndrome (MDS).
Patients and Methods
We examined 2,133 patients with MDS undergoing HLA-matched (n = 1,728) or -mismatched
(n = 405) allo HCT from 2000 to 2012. We used a Cox multivariable model to identify factors prognostic
of mortality in a training subset (n = 1,151) of the HLA-matched cohort. A weighted score using
these factors was assigned to the remaining patients undergoing HLA-matched allo HCT (validation
cohort; n = 577) as well as to patients undergoing HLA-mismatched allo HCT.
Results
Blood blasts greater than 3% (hazard ratio [HR], 1.41; 95% CI, 1.08 to 1.85), platelets 503 109/L or
less at transplantation (HR, 1.37; 95%CI, 1.18 to 1.61), Karnofsky performance status less than 90%
(HR, 1.25; 95% CI, 1.06 to 1.28), comprehensive cytogenetic risk score of poor or very poor (HR,
1.43; 95%CI, 1.14 to 1.80), and age 30 to 49 years (HR, 1.60; 95% CI, 1.09 to 2.35) were associated
with increased hazard of death and assigned 1 point in the scoring system. Monosomal karyotype
(HR, 2.01; 95% CI, 1.65 to 2.45) and age 50 years or older (HR, 1.93; 95% CI, 1.36 to 2.83) were
assigned 2 points. The 3-year overall survival after transplantation in patients with low (0 to 1 points),
intermediate (2 to 3), high (4 to 5) and very high ($ 6) scores was 71% (95% CI, 58% to 85%), 49%
(95% CI, 42% to 56%), 41% (95% CI, 31% to 51%), and 25% (95% CI, 4% to 46%), respectively
(P , .001). Increasing score was predictive of increased relapse (P , .001) and treatment-related
mortality (P , .001) in the HLA-matched set and relapse (P , .001) in the HLA-mismatched cohort.
Conclusion
The proposed system is prognostic of outcome in patients undergoing HLA-matched and -mis-
matched allo HCT for MDS.
J Clin Oncol 34:1864-1871. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Myelodysplastic syndrome (MDS) is a progressive
disorder characterized by defective myeloid pro-
genitor cell maturation resulting in blood cyto-
penias and increased likelihood of progression to
acute myelogenous leukemia.1,2 Among avail-
able therapies, only allogeneic hematopoietic cell
transplantation (allo HCT) is considered cura-
tive.3-6 The decision to proceed with allo HCT,
however, is complicated by several factors, including
the potential for transplantation-related mortality
(TRM), disease heterogeneity, and patient comor-
bidities and preference.7,8
Several prognostic tools, such as the standard
(IPSS) and revised International Prognostic Scoring
System (IPSS-R), use disease-specific factors to
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determine patient prognosis.9,10 The IPSS-R includes updated
cytogenetic classifications, incorporates patient age, and offers greater
prognostic value over the IPSS.11,12 Despite this, the IPSS is typically
used to determine disease-specific transplantation eligibility and has
been integrated into the National Comprehensive Cancer Network
guidelines.13 The rationale for this algorithm is based in part on
analyses using Markov decision modeling to predict benefit of allo
HCT in populations based on IPSS score. The first of these analyses
demonstrated that younger patients with intermediate-2– or high-
risk MDS benefited from myeloablative allo HCT at diagnosis,
whereas patients with lower-risk disease did not.14 Koreth et al15
updated these findings in a cohort of patients undergoing reduced-
intensity conditioning allo HCT, with similar results. The IPSS-R has
also been independently validated as offering prognostic information
for post–allo HCToutcomes.11 Thus, both the IPSS and IPSS-R may
be used to determine disease-specific variables that would indicate a
benefit from transplantation.
Amajor limitation to both the IPSS and IPSS-R is that they are
not specific to patients undergoing transplantation and do not take
into account other factors that may enter into a decision to pursue
allo HCT. To address these problems, we used data from the Center
for Blood and Marrow Transplant Research (CIBMTR) registry to
identify disease-, patient-, and transplantation-specific variables
that are associated with outcome in patients undergoing allo HCT
for MDS. The primary objective of this study was to develop a risk-
stratification tool prognostic of survival after transplantation. We
applied this tool to patients undergoing HLA-matched, HLA-
mismatched sibling, or unrelated-donor allo HCT. We then
sought to determine if this tool was also prognostic of relapse,
TRM, or disease-free survival (DFS) in these populations.
PATIENTS AND METHODS
Data Source
The CIBMTR is a combined research program of the Medical College
of Wisconsin and the National Marrow Donor Program. The CIBMTR
comprises a voluntary network of more than 450 transplantation centers
worldwide that contribute data on consecutive allo and autologous HCTs
to a centralized statistical center. Observational studies conducted by the
CIBMTR are performed in compliance with all applicable federal regu-
lations pertaining to the protection of human research participants.
Protected health information used in the performance of such research is
collected and maintained in the capacity of the CIBMTR as a public health
authority under the Health Insurance Portability and Accountability Act
Privacy Rule. Additional details regarding the data source are described
elsewhere.16
Patients
Patients age 18 years or older who underwent HLA-matched or
-mismatched related-donor or URD allo HCT for MDS reported to the
CIBMTR from 2000 to 2012 were included. Patients undergoing hap-
loidentical, syngeneic, umbilical cord blood, or more than two HLA loci–
or allele–mismatched URD transplantation or with missing donor data
were excluded from this analysis (n = 663). Pediatric patients (n = 262)
were also excluded. An additional 84 patients were removed because of
missing date of diagnosis, unknown graft-versus-host disease (GVHD)
prophylaxis, or missing complete 100-day follow-up data. Patients who
had bone marrow or blood blasts of 20% or greater at any time before
transplantation but who were reported as having MDS were excluded
(n = 11). A total of 1,728 patients met these criteria and underwent
HLA-matched allo HCT. An additional 405 patients underwent one to two
HLA loci–mismatched allo HCT and formed the HLA-mismatched set.
Cytogenetics were stratified based on the MDS Comprehensive
Cytogenetic Scoring System.12 The prognostic subgroups were defined
based on the following karyotype results: the very good subgroup included
del(11q) and2Y; the good subgroup included normal karyotype, del(5q),
del(12p), and del(20q); the intermediate subgroup included del(7q), +8,
i(17q), +19, and other independent clones; the poor subgroup included
inv(3), translocations involving 3q, del(3q), and complex karyotype (three
abnormalities); and the very poor subgroup included very complex kar-
yotype more than three abnormalities). Monosomal karyotype (MK) was
defined asmonosomy of two ormore chromosomes or one single autosomal
monosomy in the presence of other structural abnormalities.17 Advanced
MDS was defined as having either bone marrow blasts of 5% or greater at
HCT or French-American-British classification of refractory anemia with
excess blasts-1 or refractory anemia with excess blasts-2.18 Continuous
variables were stratified using the maximum-likelihood method and con-
firmed with false-discovery rate control.19 Overall survival (OS) and DFS
were calculated from the day of transplantation to the day of death or either
death or relapse, respectively, using the Kaplan-Meier method.
Statistical Analysis
A total of 1,728 patients who underwent HLA-matched allo HCTand
met selection criteria were randomly assigned to a training data set
comprising 67% (n = 1,151) of the cohort and a validation data set
including the remaining 33% (n = 577). The training data set was used to
develop a prognostic scoring system, and the validation data set was used to
assess the prognostic ability of the scoring system. A Cox proportional
hazards model with a stepwise selection procedure was used to select
significant covariates for OS. Maximum likelihood from the Cox model
was used to establish cutoffs for continuous variables. Forward-selection
and backward-elimination procedures were used to confirm the significant
covariates. Interaction between significant covariates was examined, and
proportional hazards assumption was examined. On the basis of the
magnitude of the hazard ratios (HRs) associated with variables, a weighted
score was assigned to factors positively associated with OS in the training
cohort. HRs between 1.25 and 1.79 were assigned 1 point, whereas HRs of
1.8 or greater were assigned 2 points. Scores were grouped based on associated
HRs into good-, intermediate-, high-, and very high–risk groups. Patients
with missing data were included in the multivariable Cox model analysis but
were excluded from analysis of the final risk score in the training and val-
idation sets. Cause-specific HRs are reported in the analysis of secondary end
points with competing events. These results were confirmed using the Fine
and Gray method to account for competing risks.20 Concordance indices
were calculated for the proposed prognostic scoring system as well as the IPSS
and IPSS-R using the validation cohort as previously described.21
RESULTS
Patients
Patient data for the HLA-matched validation and training sets
and for the HLA-mismatched set are listed in Table 1 and Appendix
Table A1 (online only), respectively. The median follow-up of
survivors was 52 months (range, 3 to 169) in the HLA-matched
training cohort, 48 months (range, 3 to 145) in the HLA-matched
validation cohort, and 46 months (range, 4 to 145) in the HLA-
mismatched cohort. The percentage of patients for whom follow-
up data were reported was 98%, 90%, and 88% at 1, 3, and 5 years,
respectively, in the combined training and validation cohorts. To
validate uniformity between the training and validation cohorts,
we calculated the incidence of relapse and TRM as well as OS and
DFS in each group. OS at 1, 3, and 5 years was 59%, 43%, and 39%
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in the training cohort and 60%, 47%, and 39% in the validation
cohort, respectively (P = not significant). The 3-year incidences of
relapse and TRM were 25% (95% CI, 22% to 28%) and 34% (95%
CI, 31% to 37%) in the training cohort and 25% (95% CI, 22% to
29%) and 31% (95% CI, 27% to 35%)in the validation cohort,
respectively (P = not significant).
Development of Prognostic Scoring System
We constructed a Cox proportional hazards model using
the HLA-matched training set that included the following varia-
bles: patient age; sex; and Karnofsky performance status; disease
stage at transplantation; comprehensive cytogenetic risk status;
bone marrow and peripheral blood blast percentages; hemoglobin,
neutrophil, and platelet counts at diagnosis and pretransplantation;
lactate dehydrogenase at transplantation; pretransplantation therapy
(hypomethylating agents, chemotherapy, neither, or both); time from
diagnosis to transplantation; year of transplantation; conditioning
regimen and regimen intensity (myeloablative v reduced intensity);
donor–recipient sex match or mismatch; GVHD prophylaxis; graft
type (bone marrow v peripheral blood); presence of secondary MDS;
and URD versus related donor.
Table 2 summarizes the variables relevant to OS identified in the
multivariable analysis of the 1,151 patients in the HLA-matched
training cohort. This multivariable model identified five inde-
pendent predictors of survival: age, Karnofsky performance status
less than 90%, cytogenetics, blood blasts greater than 3% at the time
of HCT, and platelet count 503 109/L or less at the time of HCT. On
the basis of anHRof 1.8 or higher, a weighted score of 2 was assigned
to older age (. 50 years) and monosomal karyotype, whereas other
factors were assigned a score of 0 or 1 based on an HR of less than
1.25 and 1.25 to 1.79, respectively (Appendix Table A2, online only).
The overall score ranged from 0 to 7, with increasing scores indi-
cating greater risk. On the basis of these data, we created a four-
category system: low, score of 1 or lower; intermediate, score of 2 to
3; high, score of 4 to 5; and very high, score of 6 or higher. The HR
for death (using the low-risk group as reference) was 1.76 (95% CI,
1.24 to 2.49) for the intermediate-risk group, 2.87 (95% CI, 1.99 to
4.14) for the high-risk group, and 6.75 (95% CI, 4.28 to 10.67) for
the very high–risk group (overall P , .001; Table 3).
Important variables that were not associated with OS in the
multivariable analysis included donor source (sibling v unrelated),
conditioning intensity, GVHD prophylaxis, and bone marrow
blasts at the time of transplantation. Factors associated with worse
Table 1. Demographic and Clinical Characteristics of HLA-Matched Validation
and Training Cohorts
Characteristic
No. (%)
P
Training
(n = 1,151)
Validation
(n = 580)
Age, years .67
Median 56 56
Range 18-77 19-77
Male sex 693 (60) 352 (61) .85
KPS, % .88
90-100 702 (61) 361 (62)
, 90 386 (34) 188 (32)
Missing 63 (5) 31 (5)
Secondary disorder .93
No 898 (78) 448 (77)
Yes 222 (19) 116 (20)
Missing 31 (3) 16 (3)
Cytogenetic status .92
MK positive 195 (17) 94 (16)
Very good 9 (, 1) 7 (1)
Good 440 (38) 233 (40)
Intermediate 272 (24) 131 (23)
Poor 128 (11) 62 (11)
Very poor 21 (2) 13 (2)
Missing 86 (7) 40 (7)
Blast in marrow before HCT, % .84
# 2 497 (43) 239 (41)
2-5 236 (21) 121 (21)
5-10 209 (18) 105 (18)
. 10 90 (8) 45 (8)
Missing 119 (10) 70 (12)
Blast in blood before HCT, % .67
# 3 877 (76) 448 (77)
. 3 89 (8) 38 (7)
Missing 185 (16) 94 (16)
Platelet count before HCT, 3 109/L .84
# 50 489 (42) 242 (42)
. 50 658 (57) 335 (58)
Missing 4 (, 1) 3 (, 1)
ANC before HCT, /mL .50
$ 800 682 (59) 347 (60)
, 800 420 (36) 215 (37)
Missing 49 (4) 18 (3)
Elevated LDH before HCT .87
No 677 (59) 346 (60)
Yes 327 (28) 165 (28)
Missing 147 (13) 69 (12)
IPSS at diagnosis .71
Low 28 (2) 13 (2)
Intermediate-1 412 (36) 215 (37)
Intermediate-2 381 (33) 202 (35)
High 98 (9) 40 (7)
Missing 232 (20) 110 (19)
Pretransplantation therapy .55
Hypomethylating agents only 378 (33) 189 (33)
Chemotherapy only 71 (6) 33 (6)
Both 23 (2) 19 (3)
None 646 (56) 325 (56)
Missing 33 (3) 14 (2)
Conditioning regimen intensity .89
Myeloablative 662 (58) 334 (58)
Reduced 338 (29) 174 (30)
Nonmyeloablative 127 (11) 63 (11)
Missing 24 (2) 9 (2)
Graft type .64
Bone marrow 221 (19) 106 (18)
Peripheral blood 930 (81) 474 (82)
Ex vivo T-cell depletion 29 (3) 11 (2) .93
(continued in next column)
Table 1. Demographic and Clinical Characteristics of HLA-Matched Validation
and Training Cohorts (continued)
Characteristic
No. (%)
P
Training
(n = 1,151)
Validation
(n = 580)
ATG or alemtuzumab 335 (29) 174 (30) .09
Type of donor .92
Sibling 491 (43) 246 (42)
Unrelated 660 (57) 334 (58)
Abbreviations: ANC, absolute neutrophil count; ATG, antithymocyte globulin;
HCT, hematopoietic cell transplantation; IPSS, International Prognostic Scoring
System; KPS, Karnofsky performance status; LDH, lactate dehydrogenase; MK,
monosomal karyotype.
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OS on univariable but not on multivariable analysis were RBC
transfusion dependence (HR, 1.23; 95% CI, 1.05 to 1.44; P = .009),
presence of secondary MDS (HR, 1.22; 95% CI, 1.01 to 1.47;
P = .04), and advanced disease at transplantation (HR, 1.25; 95%
CI, 1.07 to 1.47; P = .005). Although higher percentage of bone
marrow blasts was associated with presence of blood blasts, bone
marrow blast percentage alone was not prognostic of survival.
Validation of Prognostic Scoring System
We then used the scoring system to calculate a risk score for
individuals in the training cohort for whom complete data on all five
variables were available (n = 839). On the basis of these data, we
applied the score to the HLA-matched validation cohort (Table 3).
Complete data for all variables were missing for 150 patients. We
analyzed relapse and TRM incidence and OS in the patients with
missing data versus those with complete data and found no difference
in any of these outcomes. Therefore, the 150 patients with missing
data were excluded, leaving 427 patients in the analysis. Among these
427 patients, the scoring system was associated with OS (P , .001;
Table 3). The 3-year OS in the HLA-matched validation cohort was
71% (95%CI, 58% to 85%) in low-risk, 49% (95% CI, 42% to 56%)
in intermediate-risk, 41% (95% CI, 31% to 51%) in high-risk, and
25% (95% CI, 4% to 46%) in very high–risk patients (Fig 1A).
Because the training set was developed based on OS and not
other outcomes, we combined the 839 patients from the training
cohort with the 427 patients from the validation cohort for analysis
of secondary objectives (Table 4). In the combined HLA-matched
cohort, the scoring system was associated with relapse (P , .001),
TRM (P , .001), and DFS (P , .001).
Application ofMDS Scoring System in HLA-Mismatched
Cohort
The prognostic score was applied to an additional cohort of
405 patients undergoing one to two HLA loci–mismatched allo
HCT. Complete data were available for 289 patients, who were
analyzed in this set. When compared with the HLA-matched cohort,
HLA-mismatched patients were more likely to have poor-risk
karyotype (11% v 16%; P , .001), undergo reduced-intensity
conditioning (31% v 39%; P = .003), receive a bone marrow graft
(19% v 25%; P = .009), or receive antithymocyte globulin or
alemtuzumab with conditioning (29% v 43%; P , .001; Appendix
Table A1). The 1-, 3-, and 5-year OS were 46%, 34%, and 27% in
the HLA-mismatched cohort, respectively. In the HLA-mismatched
cohort, the 3-year incidence of TRM was 42% (95% CI, 37% to
47%), and relapse was 25% (95% CI, 21% to 30%). The prognostic
score was prognostic of relapse in this cohort (P = .04) but not TRM
(P = .82), DFS (P = .21), or OS (P = .13; Fig 1B).
Comparison of Proposed Scoring SystemWith IPSS and
IPSS-R
To determine if the proposed scoring system was superior to
the IPSS or IPSS-R prognostic tool, we compared the three scoring
systems in the HLA-matched validation set. We first generated a
cross table of proposed patient classifications (rows), with IPSS-R
classifications represented in colors on the x-axis (Fig 2). We found
that the systems generally agreed on patients at very high risk;
however, the proposed system resulted in significant reclassifica-
tion of patients in the low-, intermediate-, and high-risk classi-
fications. To quantify which prognostic system better fit actual
outcomes, we calculated a concordance index including 384 patients
for whom complete data were available for the IPSS, IPSS-R, and
proposed systems. Concordance indices describe the probability
that predicted and observed survival times are similar among
ranked pairs within a given system.22 As the prognostic capability
Table 2. Multivariable Analysis of Factors AssociatedWith OS in HLA-Matched
Training Cohort
Factor
No. of
Patients
HR for Death
(95% CI) P
Patient age, years .003
18-29 77 1 (reference)
30-49 289 1.60 (1.09 to 2.35)
$ 50 785 1.93 (1.36 to 2.83)
KPS, % .014
90-100 702 1 (reference)
, 90 386 1.25 (1.06 to 1.28)
Cytogenetics , .001
Very good, good,
or intermediate
720 1 (reference)
Poor or very poor 149 1.43 (1.14 to 1.80)
MK 195 2.01 (1.65 to 2.45)
Blood blast before HCT, % .005
# 3 877 1 (reference)
. 3 89 1.41 (1.08-1.85)
Platelet count before
HCT, 3 109/L
, .001
. 50 658 1 (reference)
# 50 489 1.37 (1.18 to 1.61)
Abbreviations: HCT, hematopoietic cell transplantation; HR, hazard ratio; KPS,
Karnofsky performance status; OS, overall survival.
Table 3. OS by Prognostic Score in HLA-Matched Training and Validation Cohorts
Risk Group
Training Cohort Validation Cohort
No. of Patients HR (95% CI) P No. of Patients HR (95% CI) P
Low (0-1) 98 1.00 47 1.00
Intermediate (2-3) 459 1.76 (1.24 to 2.49) .0017 258 1.66 (1.01 to 2.71) .045
High (4-5) 237 2.87 (1.99 to 4.14) , .001 104 2.29 (1.35 to 3.87) .002
Very high ($ 6) 45 6.75 (4.28 to 10.67) , .001 18 5.02 (2.48 to 10.15) , .001
Overall P* , .001 , .001
Abbreviations: HR, hazard ratio; OS, overall survival.
*Wald test.
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of a system improves, the concordance index will approach 1. We
found the concordance index for the proposed scoring system to be
0.575, compared with 0.538 and 0.554 for the IPSS and IPSS-R,
respectively, indicating a modest improvement in prognostic
capability using the proposed model.
DISCUSSION
Here we present a scoring tool prognostic of outcome in patients
undergoing allo HCT for MDS. Using multivariable analysis, we
identified pretransplantation thrombocytopenia, MDS compre-
hensive cytogenetic score, patient age, performance status, and
increased blood blasts as having prognostic relevance to survival.
Selection of patients for allo HCT is largely based on the IPSS and,
more recently, the IPSS-R tools. Although both of these systems are
prognostic of outcome after allo HCT, they were not generated
specifically from patients undergoing transplantation and do not
take into account non–disease-specific factors. A recent large-scale
evaluation of the prognostic utility of the IPSS-R in patients
undergoing transplantation conducted by the European Society for
Blood and Marrow Transplantation (EBMT) found similar out-
comes between the very good–, good-, and intermediate-risk
groups as well as the poor- and very poor–risk groups.23 These
findings indicate that although the IPSS-Rmay account for disease-
specific causes of death after transplantation, a system developed
based on patient factors may offer more specificity to patients
facing potential transplantation. Here we note that the proposed
system generally agrees with the IPSS-R in the very high–risk
subcategory; however, a significant portion of patients in high- and
very high–risk IPSS-R groups were represented in the low- and
intermediate-risk proposed scoring subcategories. The 3-year
survival in patients classified as high risk with the IPSS-R was 75%;
it was 57% in those classified as low or intermediate risk with the
proposed system. The proposed system offers improved prognostic
capability, particularly for patients in the low-, intermediate-, and
high-risk subgroups. Similar to the IPSS-R, we identified cyto-
genetics as a major factor prognostic of outcome. As in the EBMT
analysis and that conducted by Della Porta et al,11 we found MK to
offer prognostic relevance beyond the other karyotype classi-
fications.23-26 Outcomes in patients with MK are poor, indicating
this group may benefit from strategies designed to prevent relapse
after allo HCT.
More recently, Armand et al27 defined the disease risk index
(DRI) using a large data set of patients undergoing transplantation
at Dana-Farber Cancer Institute. The DRI offers prognostic
information for patients undergoing allo HCT based on disease
risk and stage. In the context of MDS, the DRI defines two groups
of MDS-specific risk based on cytogenetics. The authors addi-
tionally found that the HCT comorbidity score defined by Sorror
et al28 offered further prognostic information related to patient
fitness before transplantation. In contrast, here we offer a single
score that takes into account both patient- and disease-related
factors to form a single prognostic score.
An important finding in this study is the absence of an
association between conditioning intensity and outcome. An
obvious limitation to this conclusion is bias introduced from the
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Fig 1. Overall survival in the (A) HLA-matched and (B) -mismatched cohorts by
prognostic scoring system risk classification.
Table 4. Relapse, TRM, and DFS in Combined HLA-Matched Training and Validation Cohorts by Prognostic Score
Risk Score No. of Patients
Relapse TRM DFS
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Low 139 1.00 1.00 1.00
Intermediate 696 2.09 (1.3 to 3.36) .002 1.40 (0.99 to 1.97) .0582 1.63 (1.23 to 2.15) , .001
High 332 3.71 (2.28 to 6.04) , .001 1.92 (1.33 to 2.79) , .001 2.53 (1.89 to 3.39) , .001
Very high 60 7.49 (4.11 to 13.66) , .001 4.43 (2.71 to 7.27) , .001 5.47 (3.75 to 7.98) , .001
Overall P , .001 , .001 , .001
Abbreviations: DFS, disease-free survival; HR, hazard ratio; TRM, treatment-related mortality.
1868 © 2016 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Shaffer et al
use of retrospective registry data, where patients perceived as
having greater disease-specific risk are encouraged to undergo
myeloablative therapy. We did not find any significant demo-
graphic or disease-specific differences between patients undergoing
reduced-intensity versus myeloablative conditioning; however,
it is impossible to control for all variables in a cohort such as was
analyzed here. Nevertheless, recent findings from a prospective,
randomized study conducted by the EBMT (the RICMAC
[Reduced Versus Standard Conditioning in MDS/Secondary
Acute Myelogenous Leukemia] trial) seem to confirm that
myeloablative conditioning does not confer a survival benefit.29 It
remains an open question whether specific, high-risk disease
subsets would preferentially benefit from higher-intensity con-
ditioning. Missing from this analysis are data on somatic
mutations identified by genomic technologies that have more
recently become relevant in MDS prognostication.8 As these data
become more relevant to therapeutic decisions, the next gen-
eration of prognostic tools will need to account for this in-
formation. A second limitation in this study is the use of
Karnofsky performance status, which is subjective and can vary
between clinicians or at different times during the transplantation
evaluation. More-objective tools evaluating patient fitness,
including the HCT comorbidity index, should be used as they
become available in large patient data registries. Finally, although
this scoring system demonstrated improved prognostic capacity
over the IPSS-R, the magnitude of this benefit was limited,
suggesting that incorporation of genomic aberrations will refine
systems in the future.
Despite the limitations identified, the scoring system pre-
sented here is of use to clinicians evaluating patients with MDS.
The scoring system uses readily available clinical data and can be
calculated quickly, facilitating patient consultation with respect to
allo HCT, and may also be used to identify high-risk populations
where interventions such as post–allo HCTmaintenance therapies
may be of benefit.
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Fig 2. Categorization of patients according to the proposed prognostic system versus the revised International Prognostic Scoring System (IPSS-R). Colored bars
represent IPSS-R risk stratification on the x-axis, within the stratification based on the new scoring system represented in rows. The 3-year survival (%; range) and number
of patients for each IPSS-R group within the new scoring system is provided. Survival was omitted for groups with fewer than 10 patients.
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Appendix
Table A1. Demographic and Clinical Characteristics of HLA-Matched and
-Mismatched Cohorts
Variable
No. (%)
P
Matched
(n = 1,731)
Mismatched
(n = 405)
Age, years .13
Median 56 55
Range 18-77 18-73
Male sex 1,045 (60) 231 (57)
KPS, % .12
90-100 1,063 (61) 253 (62)
, 90 574 (33) 140 (35)
Missing 94 (5) 12 (3)
Secondary disorder .44
Yes 338 (20) 85 (21)
Missing 47 (3) 7 (2)
Cytogenetic status , .001
MK positive 289 (17) 52 (13)
Very good 16 (, 1) 1 (, 1)
Good 673 (39) 134 (33)
Intermediate 403 (23) 97 (24)
Poor 190 (11) 66 (16)
Very poor 34 (2) 5 (1)
Missing 126 (7) 50 (12)
Blast in marrow before HCT, % .06
# 2 736 (43) 162 (40)
2-5 357 (21) 90 (22)
5-10 314 (18) 73 (18)
. 10 135 (8) 47 (12)
Missing 189 (11) 33 (8)
Blast in blood before HCT, % .10
# 3 1,325 (77) 316 (78)
. 3 127 (7) 38 (9)
Missing 279 (16) 51 (13)
Platelet count before HCT, 3 109/L .06
# 50 731 (42) 197 (49)
. 50 993 (57) 206 (51)
Missing 7 (, 1) 2 (, 1)
ANC before HCT, /mL .71
$ 800 1,029 (59) 235 (58)
, 800 635 (37) 151 (37)
Missing 67 (4) 19 (5)
(continued in next column)
Table A1. Demographic and Clinical Characteristics of HLA-Matched and
-Mismatched Cohorts (continued)
Variable
No. (%)
P
Matched
(n = 1,731)
Mismatched
(n = 405)
Elevated LDH before HCT .58
No 1,023 (59) 243 (60)
Yes 492 (28) 119 (29)
Missing 216 (12) 43 (11)
IPSS at diagnosis .31
Low 41 (2) 7 (2)
Intermediate-1 627 (36) 130 (32)
Intermediate-2 583 (34) 138 (34)
High 138 (8) 34 (8)
Missing 342 (20) 96 (24)
Pretransplantation therapy .71
Hypomethylating agents only 567 (33) 132 (33)
Chemotherapy only 104 (6) 19 (5)
Both 42 (2) 7 (2)
None 971 (56) 234 (58)
Missing 47 (3) 13 (3)
Conditioning regimen intensity .003
Myeloablative 996 (58) 215 (53)
Reduced 543 (31) 156 (39)
Nonmyeloablative 159 (9) 34 (8)
Missing 33 (2) 0
Donor–recipient sex match .48
Male–Male 693 (40) 153 (38)
Male–Female 397 (23) 89 (22)
Female–Male 342 (20) 77 (19)
Female–Female 281 (16) 81 (20)
Missing 18 (1) 5 (1)
Graft type .009
Bone marrow 327 (19) 100 (25)
Peripheral blood 1,404 (81) 305 (75)
Ex vivo T-cell depletion 40 (2) 13 (3) .20
ATG or alemtuzumab 510 (29) 174 (43) , .001
Abbreviations: ANC, absolute neutrophil count; ATG, antithymocyte globulin;
HCT, hematopoietic cell transplantation; IPSS, International Prognostic Scoring
System; KPS, Karnofsky performance status; LDH, lactate dehydrogenase; MK,
monosomal karyotype.
Table A2. Calculation of Prognostic Scoring System
Prognostic Variable
Score Value
0 1 2
Age, years 18-29 30-49 $ 50
KPS, % 90-100 , 90
Comprehensive cytogenetic score* Intermediate, good, or very good Poor or very poor MK
Blood blasts at transplantation, % # 3 . 3
Platelet count at transplantation, 3 109/L . 50 # 50
Abbreviations: KPS, Karnofsky performance status; MK, monosomal karyotype.
*Very good, 2Y and del(11q); good, normal, del(5q), del(12p), del(20q), and double including del(5q); intermediate, del(7q), +8, +19, i(17q), and any one or two
abnormalities; poor, 27, inv(3), t(3q), del(3q), double including 27/del(7q), any three abnormalities; very poor, more than three abnormalities.
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